Johan Cruyff and Lung Cancer: Remembering a Football Legend

What was made public

Johan Cruyff, the Dutch player and coach who reshaped how football is played, announced in late October 2015 that he had lung cancer. About a month before his death he told reporters, "I have the feeling that I am 2-0 up in the first half. The game is not over yet." He died in Barcelona on March 24, 2016, at the age of 68. His family said he "died peacefully in Barcelona, surrounded by his family after a hard fought battle with cancer."

Contemporary reports noted that he had smoked cigarettes for most of his life and stopped after heart bypass surgery in 1991. The specific type of his lung cancer was never disclosed publicly, and no reputable source describes his treatment in detail, so this article does not guess at either.

A word about that smoking history, because it invites a conclusion the evidence cannot support. Smoking raises risk enormously across populations, but no individual case can be traced to a single cause, and nothing here is a judgment about one man's life.

Two diseases sharing one name

Doctors split lung cancer into small cell lung cancer and non-small cell lung cancer, and the difference drives everything that follows. Non-small cell disease accounts for the large majority. NCI breaks it into three main forms: adenocarcinoma at roughly 40 percent of cases, squamous cell carcinoma at about 25 percent, and large cell carcinoma at about 10 percent.

The scale is hard to overstate. For 2026 the American Cancer Society projects 229,410 new cases of lung and bronchus cancer and 124,990 deaths in the United States, the pair NCI's SEER Stat Facts page now carries. That is 10.8 percent of new cancer diagnoses but 20.0 percent of cancer deaths, and the gap between those two figures is the whole problem.

Smoking is the dominant risk factor, and NCI puts the risk for smokers at roughly tenfold that of lifetime nonsmokers. Other established risks include secondhand smoke, radon, air pollution, family history, HIV infection, and workplace exposure to asbestos, arsenic, chromium, beryllium, and nickel.

What it feels like, and what it often does not

Early lung cancer frequently causes nothing at all. NCI notes that it is sometimes found by accident on a scan ordered for another reason. When symptoms do arrive, NCI lists:

• Chest discomfort or pain.
• A cough that does not go away or gets worse over time.
• Trouble breathing, or wheezing.
• Blood in sputum, the mucus coughed up from the lungs.
• Hoarseness, or trouble swallowing.
• Loss of appetite, unexplained weight loss, and fatigue.
• Swelling in the face or in the veins of the neck.

When to get checked

The NHS gives a usable threshold for the commonest symptom: see a doctor about a cough that has not gone away after three weeks, or a long-standing cough that has changed for the worse.

Book an appointment promptly for any of these:

• Coughing up blood, even once, and even a small amount.
• Breathlessness on tasks you managed easily six months ago.
• A hoarse voice lasting more than three weeks with no cold to explain it.
• Two or more chest infections in a short span.
• Weight loss you did not intend, or appetite that has fallen away.
• New swelling of the face or neck veins, which needs urgent assessment.

Most people with these symptoms do not have lung cancer. The point of the visit is a chest x-ray or a CT scan that settles the question.

Confirming and staging it

The workup usually starts with a chest x-ray and a contrast-enhanced CT scan, but imaging alone cannot make the diagnosis. A sample of tissue or fluid is required, obtained by fine-needle aspiration, bronchoscopy, thoracoscopy, thoracentesis, or mediastinoscopy, depending on where the abnormality sits.

Staging then answers how far the disease has traveled, using PET scans, brain MRI, and bone scans. Pulmonary function tests measure how well the lungs work, which shapes whether surgery is possible.

NCI stresses that an experienced lung cancer pathologist must review the material, because separating small cell from non-small cell disease changes the treatment plan entirely.

Treatment follows the tumor's biology

For disease caught while it is confined, surgery is the mainstay. A lobectomy removes one lobe of a lung, and a pneumonectomy removes an entire lung. Stereotactic body radiation therapy delivers precisely aimed high-dose radiation and is an option for some tumors.

Beyond that, the last two decades changed the field. Tumor tissue is now tested for alterations in genes including EGFR, ALK, BRAF, ROS1, RET, NTRK, MET, KRAS, and HER2. NCI notes that ALK fusion genes turn up in 3 to 7 percent of unselected cases, and that EGFR changes are most common in adenocarcinomas arising in people who never smoked. Where a match exists, a targeted drug can be used. Immunotherapy and chemotherapy fill out the options.

Screening, and who qualifies

Lung cancer is one of the few cancers with a proven screening test. The US Preventive Services Task Force gives a grade B recommendation for annual low-dose CT in adults aged 50 to 80 who have a 20 pack-year smoking history and who currently smoke or quit within the past 15 years. A 20 pack-year history is roughly a pack a day for 20 years. Screening stops after 15 smoke-free years, or if health problems would rule out curative surgery.

The evidence comes from the National Lung Screening Trial, which found a 20 percent reduction in lung cancer deaths compared with chest x-ray, with 320 people needing to be screened to prevent one death. The harms are real too. Roughly 23 percent of NLST screening rounds produced a false positive, which can lead to procedures that were never needed.

What the numbers show

Stage at diagnosis drives outcomes more than anything else. For people diagnosed between 2016 and 2022, SEER reports five-year relative survival of 65.5 percent for localized disease, 38.2 percent for regional spread, and 10.5 percent when the cancer has reached distant sites.

The trouble is that 51 percent of cases are already distant when found, and only 24 percent are localized. Overall five-year relative survival was 29.5 percent for people diagnosed from 2016 to 2022.

Every one of these figures describes a large group of people diagnosed in past years, before some current treatments existed. None of them predicts what will happen to one person.

Sources

• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/hp/lung-screening-pdq
• https://www.cancer.gov/types/lung/patient/lung-screening-pdq
• https://seer.cancer.gov/statfacts/html/lungb.html
• https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
• https://www.nhs.uk/conditions/lung-cancer/symptoms/
• https://www.skysports.com/football/news/11827/10216592/johan-cryuff-dies-of-cancer-at-age-of-68
• https://www.aljazeera.com/sports/2016/3/24/johan-cruyff-dutch-football-icon-dies-at-68